Questioning the governance of pharmacogenomics and personalized medicine for global health

Current Pharmacogenomics and Personalized Medicine

Volumn 11, Issue 4, 2013, Pages 253-256

  Dove, Edward S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Emerging biotechnologies; Global health; Governance; Knowledge based innovation; Personalized medicine; Pharmacogenomics

Indexed keywords

DECISION MAKING; ECOSYSTEM; EDITORIAL; GOVERNMENT; HEALTH CARE ORGANIZATION; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POLICY; PROFESSIONAL KNOWLEDGE; PUBLIC-PRIVATE PARTNERSHIP;

EID: 84894095239     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692111999131125160410     Document Type: Editorial

References (17)

1. Diderot D. Supplément au voyage de Bougainville. Jimack P (trans). London: Grant & Cutler, 1988.
2. Prainsack B, Naue U. Relocating health governance: personalized medicine in times of 'global genes'. Per Med 2006; 3(3): 349-55.
3. Wynne B. Daring to imagine. India Seminars. 2009. Available from: http://www.india-seminar.com/2009/597/597_brian_wynne. htm [Accessed September 20, 2013].
4. Annan KA. Partnerships for Global Community 1998: Annual Report of the Work of the Organization. New York: United Nations, Dept. of Public Information, 1998.
5. Daudelin G, Lehoux P, Abelson J, et al. The integration of citizens into a science/policy network in genetics: governance arrangements and asymmetry in expertise. Health Expect 2010; 14: 261-71.
6. Dove ES, Faraj SA, Kolker E, et al. Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action. Genome Med 2012; 4(11): 91.
7. Flores M, Glusman G, Brogaard K, et al. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med 2013; 10(6): 565-76.
8. Özdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and Genomics without Borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr Pharmacogenomics Person Med 2011; 9(1): 1-5.
9. Munroe JB. A coalition to drive personalized medicine forward. Per Med 2004; 1(1): 9-13.
10. Hogarth S. Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States. Innovation (Abingdon) 2012; 25(4): 441-60.
11. Dove ES, Özdemir V. All the postgenomic world is a stage: the actors and narrators required for translating pharmacogenomics into public health. Per Med 2013; 10(3): 213-6.
12. Dove ES, Joly Y, Knoppers BM. Power to the people: a wikigovernance model for biobanks. Genome Biol 2012; 13: 158.
13. Latour B. Paris, invisible city: the plasma. City, Culture and Society 2012; 3: 91-3.
14. McAdam D. Political Process and the Development of Black Insurgency, 1930-1970. Chicago: University of Chicago Press, 1999.
15. Özdemir V, Fisher E, Dove ES, et al. End of the beginning and public health pharmacogenomics: knowledge in 'Mode 2' and P5 medicine. Curr Pharmacogenomics Person Med 2012; 10(1): 1-6.
16. Gross M. 'Objective culture' and the development of nonknowledge: Georg Simmel and the reverse side of knowing. Cultural Sociology 2012; 6(4): 422-37.
17. Bauman Z. Liquid Modernity. London: Polity, 2000.